Alectinib Hydrochloride

5 trials 2 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

4 Sponsors

17 Countries

Phase III

Phase II

Phase III: 3 Phase II: 2

Oversight events:

2 urgent safety measures across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 2 Anaplastic lymphoma kinase gene mutation 1 Renal cell carcinoma 1 Triple negative breast cancer 1 Ovarian cancer 1 Non-small cell lung cancer stage IV 1 Squamous cell carcinoma of head and neck 1 Skin cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 Nuvalent Inc. 1 Oslo University Hospital HF 1 Region Hovedstaden 1

All trials

5 total

A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting

2024-517553-26-00 Phase III 13 countries Nuvalent Inc.
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Phase III 11 countries F. Hoffmann-La Roche AG
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Phase II 1 country Region Hovedstaden
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended

2023-506859-13-00 Phase III 4 countries F. Hoffmann-La Roche AG

Showing 1–5 of 5 trials

← All drugs A–Z